On this page
Accretion Dilution Analysis: Does the Deal Add EPS?
Accretion/dilution analysis is the quick test bankers run to tell whether an acquisition will raise or lower the acquirer's earnings per share in the first full year after close. Accretive means higher EPS. Dilutive means lower.
Key Takeaways
- Accretion/dilution analysis compares pro-forma EPS of the combined entity to the acquirer's standalone EPS for year one post-close.
- A stock-financed deal is generally accretive when the acquirer's P/E multiple exceeds the target's, because it is buying earnings cheaply.
- A deal accretive on EPS can still destroy shareholder value if the purchase price exceeds the target's intrinsic value.
- Intangible amortization from purchase accounting is a non-cash charge that analysts often strip out, so deals are shown both ways.
Key Takeaways
- Accretion/dilution analysis compares pro-forma EPS of the combined entity to the acquirer's standalone EPS for year one post-close.
- A stock-financed deal is generally accretive when the acquirer's P/E multiple exceeds the target's, because it is buying earnings cheaply.
- A deal accretive on EPS can still destroy shareholder value if the purchase price exceeds the target's intrinsic value.
- Intangible amortization from purchase accounting is a non-cash charge that analysts often strip out, so deals are shown both ways.
What It Is
The analysis compares two numbers side by side. On the left is the acquirer's standalone EPS for a forward period, usually year one or year two after close. On the right is the pro forma EPS of the combined company for the same period, built by adding the target's net income to the acquirer's, adjusting for financing costs and synergies, and dividing by the new share count.
If pro forma EPS is higher than the standalone number, the deal is accretive. If it is lower, the deal is dilutive. The percentage change is the headline figure cited in deal announcements and fairness opinions.
The Intuition
Public-market investors watch earnings per share as a shorthand for value delivered per share owned. Management teams know this and often structure deals to show accretion early. The analysis is a sanity check that asks a simple question. Does the cash, stock, or debt used to buy the target produce more earnings for each share of the acquirer than existed before?
Accretion/dilution does not tell you whether a deal creates value. A dilutive deal can still be wealth-creating if the target holds strategic assets or growth that EPS does not capture. An accretive deal can destroy value if the acquirer is paying too much and simply borrowing its way to a higher short-term number. The analysis is a first-pass filter, not a verdict.
How It Works
Four inputs drive the result: the target's contribution to net income, the financing mix, the cost of that financing, and expected synergies.
Pro forma net income = Acquirer NI + Target NI + After-tax synergies - After-tax new interest expense - Lost interest on cash used
Pro forma shares = Acquirer shares + New shares issued in the deal
Pro forma EPS = Pro forma net income / Pro forma shares
Accretion % = (Pro forma EPS - Standalone EPS) / Standalone EPS
Cash deals use the acquirer's balance-sheet cash or new debt. They are usually accretive in the near term because cash earns little and debt interest is tax-deductible, so swapping a low-yielding asset for target earnings boosts EPS.
Stock deals issue new acquirer shares to target holders at an agreed exchange ratio. A widely cited rule of thumb says a stock-financed acquisition is accretive when the acquirer's price-to-earnings multiple is higher than the target's. The acquirer is buying earnings at a lower multiple than it trades at, so each new share brings in more income than it dilutes.
Debt deals sit between the two. Rising interest expense drags on pro forma earnings, but the tax shield softens the hit. Whether the deal is accretive depends on the spread between the target's earnings yield and the after-tax cost of debt.
Analysts usually build the model for year one and year two post-close, separate from synergies so the reader can see the underlying deal economics. A separate line shows the incremental impact of cost or revenue synergies phased in over time.
Worked Example
Acquirer trades at $50 with 100 million shares outstanding and net income of $500 million. Standalone EPS is $5.00. Target has 20 million shares at $60, net income of $60 million, and EPS of $3.00. The acquirer offers $70 per share in an all-cash deal funded with new debt at 5 percent pre-tax. The tax rate is 25 percent.
Deal size: 20 million times $70 equals $1.4 billion in new debt. After-tax interest expense: 1.4 billion times 5 percent times (1 minus 0.25) equals $52.5 million per year.
Pro forma net income: 500 plus 60 minus 52.5 equals $507.5 million. Pro forma shares: 100 million, unchanged because no stock was issued. Pro forma EPS: 507.5 divided by 100 equals $5.075.
Accretion: (5.075 minus 5.00) divided by 5.00 equals 1.5 percent accretive in year one, before any synergies. Add $40 million in after-tax synergies and pro forma EPS rises to $5.475, or roughly 9.5 percent accretion.
Common Mistakes
-
Confusing accretion with value creation. A deal that is accretive on EPS can still destroy shareholder value if the acquirer overpays. EPS captures financing and earnings arithmetic, not whether the purchase price exceeded the target's intrinsic value. Damodaran has written at length on how synergy numbers are routinely overstated in deal models.
-
Ignoring the source of accretion. If accretion comes entirely from using cheap debt, the acquirer has added leverage risk that is not visible in the EPS figure. A highly accretive but highly levered deal can look worse once you adjust for the increased probability of financial distress.
-
Double-counting synergies. Cost synergies, revenue synergies, and tax synergies are often modeled separately and then summed without checking for overlap. Facility consolidation, for example, can show up in both cost savings and capex reduction lines.
-
Forgetting amortization of intangibles. Purchase accounting creates new intangible assets that are amortized through the income statement. Analysts often present accretion both before and after this non-cash charge to avoid penalizing the deal for a bookkeeping effect.
-
Using peak-cycle earnings as the baseline. If the target's standalone EPS is inflated by a cyclical high, accretion in year one looks strong but reverses when earnings normalize. A through-cycle or normalized earnings view prevents this trap.
Frequently Asked Questions
Q: What is accretion/dilution analysis in simple terms? It is a quick test that asks: will this acquisition raise or lower the acquirer's earnings per share in the first year after close? Accretive means higher EPS; dilutive means lower. Bankers run it early in deal discussions to screen basic financial compatibility.
Q: How does accretion/dilution analysis affect investment decisions? An accretive deal often gets a better initial market reaction, but accretion is not the same as value creation. A deal can be accretive on EPS while destroying intrinsic value if the acquirer overpaid. Use the analysis as a first-pass filter, not a verdict on whether the deal is good.
Q: What is a real-world example of the accretion calculation? Acquirer earns $500M with 100M shares ($5.00 EPS). It buys a target with $60M net income using $1.4B of 5% debt (after-tax interest: $52.5M). Pro forma NI = $500M + $60M - $52.5M = $507.5M. Same 100M shares, so EPS = $5.075, 1.5% accretive before synergies.
Q: How can investors use accretion/dilution analysis correctly? Separate the EPS accretion attributable to financial engineering (debt funding, share count changes) from organic improvement. If a deal is accretive only because of cheap leverage, the EPS lift comes with balance-sheet risk that EPS doesn't show. Also check the year-2 number, where synergy phase-in and integration costs become clearer.
Q: How is accretion/dilution analysis different from a DCF valuation? Accretion/dilution is a near-term EPS arithmetic test; it says nothing about intrinsic value or whether the purchase price was fair. A DCF valuation discounts the deal's long-term cash flows at the appropriate cost of capital to test whether present value exceeds the price paid, a much deeper, and more relevant, question.
Sources
- Macabacus. "Accretion/Dilution Analysis." https://macabacus.com/valuation/accretion-dilution
- Wall Street Prep. "Accretion/Dilution Analysis: M&A Model Tutorial." https://www.wallstreetprep.com/knowledge/accretion-dilution-analysis/
- Corporate Finance Institute. "Accretion Dilution Analysis." https://corporatefinanceinstitute.com/resources/financial-modeling/accretion-dilution-analysis/
- Damodaran, A. "The Value of Synergy." NYU Stern. https://pages.stern.nyu.edu/~adamodar/New_Home_Page/papers/synergy.pdf
Disclaimer
This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.